- Home
- DDI vs PROK Comparison
DDI vs PROK Comparison
Compare DDI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- PROK
- Stock Information
- Founded
- DDI 2008
- PROK 2015
- Country
- DDI South Korea
- PROK United States
- Employees
- DDI N/A
- PROK N/A
- Industry
- DDI EDP Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DDI Technology
- PROK Health Care
- Exchange
- DDI Nasdaq
- PROK Nasdaq
- Market Cap
- DDI 431.6M
- PROK 417.1M
- IPO Year
- DDI 2021
- PROK N/A
- Fundamental
- Price
- DDI $9.25
- PROK $2.11
- Analyst Decision
- DDI Strong Buy
- PROK Strong Buy
- Analyst Count
- DDI 4
- PROK 4
- Target Price
- DDI $19.25
- PROK $6.25
- AVG Volume (30 Days)
- DDI 53.3K
- PROK 1.5M
- Earning Date
- DDI 11-10-2025
- PROK 11-10-2025
- Dividend Yield
- DDI N/A
- PROK N/A
- EPS Growth
- DDI 0.12
- PROK N/A
- EPS
- DDI 2.30
- PROK N/A
- Revenue
- DDI $346,122,000.00
- PROK $744,000.00
- Revenue This Year
- DDI $16.04
- PROK $471.74
- Revenue Next Year
- DDI $6.72
- PROK N/A
- P/E Ratio
- DDI $4.06
- PROK N/A
- Revenue Growth
- DDI 1.07
- PROK N/A
- 52 Week Low
- DDI $8.09
- PROK $0.46
- 52 Week High
- DDI $14.99
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- DDI 56.16
- PROK 34.46
- Support Level
- DDI $8.71
- PROK $2.08
- Resistance Level
- DDI $9.45
- PROK $2.25
- Average True Range (ATR)
- DDI 0.36
- PROK 0.23
- MACD
- DDI 0.04
- PROK -0.05
- Stochastic Oscillator
- DDI 77.53
- PROK 7.14
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.